Adma Biologics Inc. (NASDAQ:ADMA)’s share price fell 22.3% during mid-day trading on Monday . The stock traded as low as $5.00 and last traded at $6.10, with a volume of 775,071 shares traded. The stock had previously closed at $7.85.

Several brokerages recently issued reports on ADMA. Maxim Group reduced their price objective on Adma Biologics from $24.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, July 25th. Raymond James Financial Inc. cut Adma Biologics from a “strong-buy” rating to a “market perform” rating in a research note on Monday.

The stock’s 50 day moving average price is $6.80 and its 200-day moving average price is $6.39. The company’s market cap is $83.63 million.

Adma Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Friday, May 13th. The company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.37) by $0.06. On average, equities analysts anticipate that Adma Biologics Inc. will post ($1.38) EPS for the current fiscal year.

In other Adma Biologics news, Director Jerrold B. Grossman purchased 45,769 shares of the company’s stock in a transaction on Tuesday, May 3rd. The shares were bought at an average cost of $6.50 per share, with a total value of $297,498.50. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Adam S. Grossman purchased 200,000 shares of the company’s stock in a transaction on Tuesday, May 3rd. The stock was acquired at an average cost of $6.50 per share, for a total transaction of $1,300,000.00. The disclosure for this purchase can be found here.

ADMA Biologics, Inc is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.